Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model
Cardiovascular Intervention and Therapeutics · 2024
DOI: 10.1007/s12928-024-01023-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, 2024. Verfasst von Sho Torii und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, School of Medicine, Faculty of Medicine, Tokai University, 143 Shimokasuya, Kanagawa, 2591193, Japan. Hauptthemen laut MEDLINE: Absorbable Implants, Magnesium, Alloys, Coronary Vessels. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The objective of the study is to investigate the safety, feasibility, and degradation profile of a novel Mg alloy-based bioresorbable coronary scaffold (JFK-PRODUCT BRS) with thin struts (110 μm). Polymer- or Mg alloy-based BRSs have not replaced nondegradable metal stents because of the higher prevalence of scaffold thrombosis and restenosis in clinical practice; these poor clinical outcomes were due to inadequate scaffold designs, including thick struts (more than 150 μm) and their inappropriate degradation processes. Fourteen healthy pigs received 17 JFK-PRODUCT BRSs in the coronary arteries and were sacrificed at 1, 6, 12, 18, and 26 months after implantation. Angiography, optical coherence tomography, microfocus X-ray computed tomography (µCT), scanning electron microscopy with energy-dispersive X-ray spectrometry (SEM–EDX), and histopathological evaluation were performed. The JFK-PRODUCT had a median percent late recoil of 11.28% at 1 month. The µCT observation confirmed that scaffold discontinuity reached 64.8% at 12 months with increased scaffold inner area thereafter, suggesting artery positive remodeling. The inflammation was mild, peaked at 18 months, and decreased thereafter. The SEM–EDX analysis demonstrated gradual degradation of the scaffold with formation of inorganic deposits, presumed to be calcium phosphates. It also revealed the disappearance of calcium phosphates at 26 months, achieving almost complete replacement of the scaffold by biocomponents. The current study demonstrated the safety and feasibility of JFK-PRODUCT with a lower acute recoil rate despite its thin struts. The scaffolds were almost completely disappeared at 26 months after implantation. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, School of Medicine, Faculty of Medicine, Tokai University, 143 Shimokasuya, Kanagawa, 2591193, Japan.
- Research Center for Macromolecules and Biomaterials, National Institute for Materials Science, Ibaraki, Japan.
- Shanghai Kepan Investment and Management CO., LTD, Shanghai, China.
- Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto, Japan.
- Japan Medical Device Technology Co., Ltd, Kumamoto, Japan.
- Department of Cardiology, Faculty of Medicine, Kindai University, Osaka, Japan. gnakazawa@med.kindai.ac.jp.
Zitieren
APA
Torii, S., Yamamoto, A., Yoshikawa, A., Lu, L., Sasaki, M., Obuchi, S., Wada, A., Tsukamoto, H., & Nakazawa, G. (2024). Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model. Cardiovascular Intervention and Therapeutics. https://doi.org/10.1007/s12928-024-01023-3
Vancouver
Torii S, Yamamoto A, Yoshikawa A, Lu L, Sasaki M, Obuchi S, et al. Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model. Cardiovascular Intervention and Therapeutics. 2024. doi:10.1007/s12928-024-01023-3
BibTeX
@article{Torii2024,
author = {Torii, Sho and Yamamoto, Akiko and Yoshikawa, Ayako and Lu, Linhai and Sasaki, Makoto and Obuchi, Shoko and Wada, Akira and Tsukamoto, Hideo and Nakazawa, Gaku},
title = {Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model},
journal = {Cardiovascular Intervention and Therapeutics},
year = {2024},
doi = {10.1007/s12928-024-01023-3}
}
EUVIMED